Cormorant Asset Management as of March 31, 2014
Portfolio Holdings for Cormorant Asset Management
Cormorant Asset Management holds 46 positions in its portfolio as reported in the March 2014 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Medivation | 8.9 | $39M | 600k | 64.37 | |
| Cubist Pharmaceuticals | 5.0 | $22M | 300k | 73.15 | |
| Puma Biotechnology (PBYI) | 5.0 | $22M | 208k | 104.14 | |
| BioMarin Pharmaceutical (BMRN) | 4.7 | $21M | 300k | 68.21 | |
| Receptos | 4.3 | $19M | 450k | 41.94 | |
| Dyax | 4.1 | $18M | 2.0M | 8.98 | |
| Intercept Pharmaceuticals In | 3.8 | $17M | 50k | 329.80 | |
| Arrowhead Research | 3.8 | $16M | 1.0M | 16.42 | |
| Idenix Pharmaceuticals | 3.5 | $15M | 2.5M | 6.03 | |
| Ptc Therapeutics I (PTCT) | 3.3 | $14M | 550k | 26.14 | |
| Jazz Pharmaceuticals (JAZZ) | 3.2 | $14M | 100k | 138.68 | |
| Prothena (PRTA) | 3.1 | $13M | 350k | 38.31 | |
| Dex (DXCM) | 2.9 | $12M | 300k | 41.36 | |
| BioCryst Pharmaceuticals (BCRX) | 2.8 | $12M | 1.2M | 10.58 | |
| Merck & Co (MRK) | 2.6 | $11M | 200k | 56.77 | |
| Sangamo Biosciences (SGMO) | 2.5 | $11M | 600k | 18.08 | |
| Acelrx Pharmaceuticals | 2.1 | $9.0M | 750k | 12.01 | |
| Sorrento Therapeutics (SRNE) | 2.1 | $9.0M | 700k | 12.82 | |
| Alkermes (ALKS) | 2.0 | $8.8M | 200k | 44.09 | |
| Tesaro | 2.0 | $8.8M | 300k | 29.48 | |
| Karyopharm Therapeutics (KPTI) | 2.0 | $8.6M | 280k | 30.89 | |
| Clovis Oncology | 1.9 | $8.3M | 120k | 69.27 | |
| Nanostring Technologies (NSTGQ) | 1.9 | $8.3M | 400k | 20.65 | |
| Array BioPharma | 1.9 | $8.2M | 1.8M | 4.70 | |
| Glycomimetics (GLYC) | 1.8 | $7.7M | 469k | 16.33 | |
| ACADIA Pharmaceuticals (ACAD) | 1.7 | $7.3M | 300k | 24.33 | |
| Chimerix (CMRX) | 1.6 | $6.9M | 300k | 22.84 | |
| Omeros Corporation (OMER) | 1.4 | $6.0M | 500k | 12.07 | |
| Galectin Therapeutics (GALT) | 1.2 | $5.3M | 348k | 15.31 | |
| Portola Pharmaceuticals | 1.2 | $5.2M | 200k | 25.90 | |
| Eagle Pharmaceuticals (EGRX) | 1.2 | $5.1M | 400k | 12.75 | |
| Rockwell Medical Technologies | 1.2 | $5.1M | 400k | 12.66 | |
| Novavax | 1.0 | $4.5M | 1.0M | 4.53 | |
| Recro Pharma | 0.8 | $3.7M | 500k | 7.32 | |
| Genvec | 0.8 | $3.5M | 1.3M | 2.65 | |
| Pacira Pharmaceuticals (PCRX) | 0.8 | $3.5M | 50k | 70.00 | |
| Alnylam Pharmaceuticals (ALNY) | 0.8 | $3.4M | 50k | 67.14 | |
| Agenus | 0.7 | $3.2M | 1.0M | 3.17 | |
| Geron Corporation (GERN) | 0.7 | $3.1M | 1.5M | 2.09 | |
| Aquinox Pharmaceuticals | 0.7 | $3.1M | 247k | 12.73 | |
| Auspex Pharmaceuticals | 0.7 | $3.1M | 100k | 30.76 | |
| Biogen Idec (BIIB) | 0.7 | $3.1M | 10k | 305.90 | |
| Ultragenyx Pharmaceutical (RARE) | 0.7 | $2.9M | 60k | 48.88 | |
| Regulus Therapeutics | 0.4 | $1.8M | 200k | 9.02 | |
| Idera Pharmaceuticals | 0.4 | $1.6M | 400k | 4.08 | |
| Celsus Therapeutics Plc sponsored adr ne | 0.1 | $669k | 103k | 6.49 |
